NeoGenomics, Inc. Operating Lease, Liability, Current
NeoGenomics, Inc. (NEO) had Operating Lease, Liability, Current of $3.72 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-07-28
- 2026-06-30: Operating Lease, Liability, Current $3.72M.
- 2026-03-31: Operating Lease, Liability, Current $4.83M.
- 2025-12-31: Operating Lease, Liability, Current $4.78M.
- 2025-09-30: Operating Lease, Liability, Current $4.51M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $3.72M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $4.83M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $4.78M 10-Q · filed 2026-07-28 |
| 2025-09-30 | $4.51M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $4.05M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $3.08M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $3.38M 10-K · filed 2026-02-17 |
| 2024-09-30 | $3.72M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $3.57M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $4.49M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $5.61M 10-K · filed 2025-02-18 |
| 2023-09-30 | $6.21M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $7.35M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $6.93M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $6.58M 10-K · filed 2024-02-20 |
| 2022-09-30 | $6.38M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.71M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $5.96M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $6.88M 10-K · filed 2023-02-24 |
| 2021-09-30 | $6.99M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.64M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $5.11M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $4.97M 10-K · filed 2022-02-25 |
| 2020-09-30 | $4.70M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $4.50M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $4.50M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $3.38M 10-K · filed 2021-02-25 |
| 2019-09-30 | $3.53M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $3.43M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.62M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |